Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
Ardelyx Inc ARDX
$4.95
▼ -1.79%
($-0.09)
📅 Earnings This Week
Open
$5.04
Prev Close
$5.04
Day Range
$4.92 – $5.05
52W Range
$4.08 – $8.40
Market Cap
$1.22B
Beta
0.70
EPS (TTM)
$-0.24
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-19 |
| Shares Out. | 247,030,000 |
| Website | ardelyx.com/ ↗ |
| Phone | 13026974590 |
| Employees | 489 |
| Revenue | $94.5M |
| Gross Profit | $89.7M |
| Net Income | -$37.6M |
| Free Cash Flow | -$37.5M |
| Total Assets | $504.5M |
| Total Liabilities | $355.9M |
| Equity | $148.6M |
About Ardelyx Inc
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx Inc is a publicly traded company under the ticker symbol ARDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)